Effects of tislelizumab on health‐related quality of life in patients with recurrent or metastatic nasopharyngeal cancer

Documenti analoghi

• Evaluating the reduction of elective radiotherapy fields for de novo metastatic nasopharyngeal carcinoma in the immunotherapy era
  di: Ting Jin, et al.
  Pubblicazione: (2024)
• Impact of salvage chemotherapy after immune checkpoint inhibitor for recurrent or metastatic head and neck cancer
  di: Takuma Matoba, et al.
  Pubblicazione: (2024)
• Loco‐regional radiotherapy in de novo metastatic nasopharyngeal carcinoma with chemotherapy and immunotherapy: A real‐world retrospective study from two cancer centers
  di: Li Ma, et al.
  Pubblicazione: (2024)
• Higher area deprivation index is associated with poorer local control and overall survival in non‐metastatic nasopharyngeal carcinoma
  di: Nauman H. Malik, et al.
  Pubblicazione: (2024)
• Sarcopenia may predict recurrence in patients with head and neck cancer
  di: Angela A. Colback, et al.
  Pubblicazione: (2024)